- ISIN
- US5011471027
- CUSIP
- 501147102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 20, 2017
Highlights
- Market Cap
- $10.06B
- Enterprise Value
- $9.56B
- EPS (TTM)
- $7.48
- PE Ratio
- 45.62
- PEG Ratio
- 0.11
- Total Revenue (TTM)
- $417.30M
- Gross Profit (TTM)
- $387.24M
- EBITDA (TTM)
- $185.45M
- Year Range
- $130.50 - $382.54
- Target Price
- $332.75
- ROA (TTM)
- 16.11%
- ROE (TTM)
- 17.63%
- Avg. Volume (1M)
- 578K
- Avg. Volume Value (1M)
- $198.37M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KRYS Performance Chart
Krystal Biotech, Inc. (KRYS) is up 38.4% since the beginning of the year. At $341 per share, KRYS is trading 10.8% below its 52-week high of $383. Investors who bought $1,000 worth of KRYS shares 5 years ago would now be looking at an investment worth $5,837.
Loading charts...
Compare this symbol against anything
Returns By Period
Krystal Biotech, Inc. (KRYS) has returned 38.36% so far this year and 117.30% over the past 12 months.
Krystal Biotech, Inc.
- 1D
- -7.01%
- 1M
- -9.05%
- 6M
- 22.16%
- YTD
- 38.36%
- 1Y
- 117.30%
- 3Y*
- 37.85%
- 5Y*
- 42.31%
- 10Y*
- —
- ALL TIME*
- 48.13%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
KRYS Monthly Returns History
Based on dividend-adjusted daily data since Sep 20, 2017, KRYS's average daily return is +0.25%, while the average monthly return is +4.31%. At this rate, an investment would double in approximately 1.4 years.
Historically, 55% of months were positive and 45% were negative. The best month was Nov 2021 with a return of +60.8%, while the worst month was May 2025 at -25.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, KRYS closed higher 51% of trading days. The best single day was Nov 29, 2021 with a return of +121.7%, while the worst single day was Mar 12, 2020 at -22.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.26% | -1.29% | -6.28% | 1.53% | 17.83% | 20.27% | -8.22% | 38.36% | |||||
| 2025 | 1.97% | 12.21% | 0.59% | -5.78% | -25.85% | 9.13% | 11.94% | -4.01% | 19.52% | 11.88% | 10.37% | 13.09% | 57.37% |
| 2024 | -10.33% | 43.34% | 11.58% | -13.94% | 4.53% | 14.74% | 13.52% | -6.40% | -6.71% | -5.22% | 14.43% | -20.65% | 26.28% |
| 2023 | 4.92% | -1.46% | -2.26% | 4.92% | 40.30% | -0.38% | 9.97% | -3.58% | -6.81% | 0.75% | -10.82% | 19.03% | 56.60% |
| 2022 | -15.65% | 7.71% | 4.70% | -8.91% | -2.85% | 11.51% | 10.54% | -3.40% | -0.58% | 9.76% | 1.62% | 1.90% | 13.25% |
| 2021 | 16.17% | 13.19% | -2.35% | 3.12% | -17.88% | 4.23% | -14.06% | -0.86% | -9.89% | -4.06% | 60.81% | -13.16% | 16.58% |
Benchmark Metrics
Krystal Biotech, Inc. has an annualized alpha of 56.54%, beta of 1.25, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since September 20, 2017.
- This stock captured 169.45% of S&P 500 Index gains but only 32.86% of its losses - a favorable profile for investors.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 56.54%
- Beta
- 1.25
- R²
- 0.10
- Upside Capture
- 169.45%
- Downside Capture
- 32.86%
Return for Risk
Risk / Return Rank
KRYS ranks 96 for risk / return — above 96% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KRYS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.58 | ||
| Sortino ratioReturn per unit of downside risk | +1.28 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.25 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 7.68 | 2.00 | +5.67 |
| Martin ratioReturn relative to average drawdown | 18.95 | 8.49 | +10.46 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Krystal Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Krystal Biotech, Inc. was 53.42%, occurring on Nov 26, 2021. Recovery took 1 trading session.
The current Krystal Biotech, Inc. drawdown is 9.79%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-53.42%Nov 2021 | 8mo 29d | 3d | 9mo 2dMar 2021 - Nov 2021 | — |
-46.65%Mar 2020 | 1mo 4d | 9mo 26d | 11moFeb 2020 - Jan 2021 | COVID crash2020 |
-44.55%May 2022 | 5mo 12d | 11mo 7d | 1y 4moNov 2021 - Apr 2023 | Bear market2022 |
-42.26%May 2025 | 10mo 3d | 6mo | 1y 3moJul 2024 - Nov 2025 | 2025 selloff2025 |
-35.34%Oct 2019 | 2mo 10d | 1mo 13d | 3mo 23dJul 2019 - Nov 2019 | — |
Drawdown Indicators
| KRYS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.42% | -56.78% | +3.36% |
Max Drawdown (1Y)Largest decline over 1 year | -15.94% | -9.10% | -6.84% |
Max Drawdown (3Y)Largest decline over 3 years | -42.26% | -18.90% | -23.36% |
Max Drawdown (5Y)Largest decline over 5 years | -44.55% | -25.43% | -19.12% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -9.79% | -1.58% | -8.21% |
Average DrawdownAverage peak-to-trough decline | -15.99% | -10.70% | -5.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.45% | 2.14% | +4.31% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Krystal Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Krystal Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for KRYS, comparing it with other companies in the Biotechnology industry. Currently, KRYS has a P/E ratio of 45.6. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for KRYS compared to other companies in the Biotechnology industry. KRYS currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KRYS relative to other companies in the Biotechnology industry. Currently, KRYS has a P/S ratio of 24.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KRYS in comparison with other companies in the Biotechnology industry. Currently, KRYS has a P/B value of 8.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KRYS
Add Krystal Biotech, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KRYS